AKT1 and cancer: The increased activation of MAPK and PI3K/Akt signaling has been observed in oxaliplatin-resistant HT29 and HCT116 cells, which could be mitigated by the anti-cancer effect of kaempferol, resulting in growth inhibition and cell cycle arrest [233].